Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Smoldering Multiple Myeloma 2

Interventions

Lenalidomide 6carfilzomib 3Dexamethasone 3daratumumab 2Melphalan 2Leflunomide 2poly ICLC 1pembrolizumab 1isatuximab 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Myelography 1Metformin 1Cyclophosphamide 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Smoldering Multiple Myeloma × Leflunomide × Clear all
NCT05014646 2026-04-30

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

City of Hope Medical Center

Phase 2 Active not recruiting
27 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT04370483 2026-01-05

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

City of Hope Medical Center

Phase EARLY_PHASE1 Active not recruiting
1 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡